Back to discover

Protein / target

MecA PBP2' (penicillin binding protein 2')

mecAQ53707Staphylococcus aureus
UniProt: Q53707
15
Clinical trials
1
Drugs targeting

Protein at a glance

Biological role

Peptidoglycan L,D-transpeptidase

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Subcellular location

Membrane
Domains and Gene Ontology detail (8)

Domains & features

NTF2-like N-terminal transpeptidasePenicillin-binding protein dimerisationPenicillin-binding protein transpeptidase

Gene Ontology

  • Cplasma membrane
  • Fpenicillin binding
  • Fpeptidoglycan L,D-transpeptidase activity
  • Pcell wall organization
  • Presponse to antibiotic

668 aa · 76 kDa

Approved medicines with mapped indications

1 medicine · 1 area

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Bacterial Infections1 medicine
ceftaroline fosamil

Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

1

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

ceftaroline fosamil
Inhibitor

Penicillin-binding protein 2a inhibitor

Indicated for Bacterial Infections

Direct interaction with this protein · 1 of 9 recorded protein targets — broad pharmacology

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Clinical trials

15

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

Bacteriophage Therapy for Mycobacterium Abscessus Pulmonary Infection: An Open Label Individual Patient StudyPHASE1

ENROLLING_BY_INVITATION · via ceftaroline fosamil · NCT07228702

A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus BacteremiaPHASE4

COMPLETED · via ceftaroline fosamil · NCT01701219

A Multicenter Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Elderly Subjects With Community-Acquired Bacterial PneumoniaPHASE4

WITHDRAWN · via ceftaroline fosamil · NCT01666743

A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects With Community-acquired Bacterial Pneumonia at Risk for Infection Due to Methicillin-resistant Staphylococcus AureusPHASE4

COMPLETED · via ceftaroline fosamil · NCT01645735

View all trials (11)
A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP)PHASE4

COMPLETED · via ceftaroline fosamil · NCT01669980

Pharmacokinetics of a Single Dose of Ceftaroline Fosamil in Children Ages Birth to Younger Than 12 Years With Suspected or Confirmed InfectionPHASE4

COMPLETED · via ceftaroline fosamil · NCT01298843

A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) vs Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities.PHASE3

TERMINATED · via ceftaroline fosamil · NCT02202135

A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With Community-acquired Bacterial Pneumonia Requiring HospitalizationPHASE2/PHASE3

COMPLETED · via ceftaroline fosamil · NCT01530763

A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying ComorbiditiesPHASE3

COMPLETED · via ceftaroline fosamil · NCT01499277

A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Ceftaroline Versus Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure InfectionsPHASE2/PHASE3

COMPLETED · via ceftaroline fosamil · NCT01400867

Open-label, Multicentre Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Ceftaroline In Neonates And Young Infants With Late-onset SepsisPHASE2

TERMINATED · via ceftaroline fosamil · NCT02424734

Phase 1/2 Trial of Ceftaroline for the Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in ChildrenPHASE1/PHASE2

COMPLETED · via ceftaroline fosamil · NCT02335905

Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftaroline in Patients With CSF DevicePHASE1

COMPLETED · via ceftaroline fosamil · NCT02806882

An Open-label, Nonrandomised, Phase I Study to Assess the Pharmacokinetics of Ceftaroline After Intravenous Administration of aSingle Dose of Ceftaroline Fosamil (200 mg) to Patients With End-stage Renal Disease Undergoing Haemodialysis When Compared to a Single Dose of Ceftaroline Fosamil (600 mg)PHASE1

COMPLETED · via ceftaroline fosamil · NCT01664065

A Phase I, Single Centre, Randomised, Double-blind, Placebo-controlled Parallel Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ceftaroline After Different Intravenous Dose Regimens of Ceftaroline Fosamil to Healthy SubjectsPHASE1

COMPLETED · via ceftaroline fosamil · NCT01612507

ClinicalTrials.gov via the drug-target graph.

What's happening now

1

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for a drug that targets this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Regulatory approval2012-08-22

    Approval: Zinforo (EMA)

    ema · regulatory · ema · via ceftaroline fosamil

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.